6 hours CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue EstimatesZacks
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 24.06% and 90.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X